UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044117
Receipt number R000048570
Scientific Title Verification of intestinal environment improvement and effect on cold symptoms by amazake long-term intake
Date of disclosure of the study information 2021/06/30
Last modified on 2022/02/18 13:18:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification of intestinal environment improvement and effect on cold symptoms by amazake long-term intake

Acronym

Verification of intestinal environment improvement and effect on cold symptoms by amazake long-term intake

Scientific Title

Verification of intestinal environment improvement and effect on cold symptoms by amazake long-term intake

Scientific Title:Acronym

Verification of intestinal environment improvement and effect on cold symptoms by amazake long-term intake

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Verification of intestinal environment improvement and effect on cold symptoms by amazake long-term intake

Basic objectives2

Others

Basic objectives -Others

Verification of effect on bowel movement by amazake long-term intake

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

alteration of intensional bacterial flora and effect on cold symptoms

Key secondary outcomes

Bowel movement


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Food

Interventions/Control_1

Amazake made by rice koji and sake lees is taken once a day

Interventions/Control_2

Placebo drink of control 3 is taken once a day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Regular visitors to Matsuike Clinic (those with mild constipation who are prescribed magnesium oxide) or healthy adults recruited by expressing their intention to participate directly with the investigator.
2) Those who are 20 to 60 years old at the time of obtaining consent to participate in the exam
3) Those who have received sufficient explanation about the purpose and contents of this test, have the ability to consent, voluntarily volunteer to participate after understanding it well, and can consent to participate in this test in writing.
4) Those who can come to the hospital on the designated date and receive interviews
5) Those who the investigator deems appropriate to participate in this study

Key exclusion criteria

1) Persons with symptoms other than mild constipation
2) Those who cannot be judged by the investigator as having no influence on the participation in the examination regarding the medical history
3) Persons who may cause allergic symptoms to the ingredients contained in the test food
4) Those who habitually consume amazake (regardless of manufacturer)
5) Those planning to become pregnant, lactating or possibly pregnant and pregnant during the study period
6) Persons with alcoholism or other mental disorders
7) Persons who may change their lifestyle during the examination period (night shift, long-term travel, etc.)
8) Those who plan to take new health foods and supplement foods during the test period
9) Those who have been treated with hospitalization within the past 6 months
10) Those who are currently participating in other human clinical trials, those who have not passed 3 months since participating in other human clinical trials
11) Others who are judged by the investigator to be inappropriate for this study

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Sadao
Middle name
Last name Mori

Organization

MORINAGA & CO., LTD.

Division name

R & D Center

Zip code

230-8504

Address

2-1-1 Shimosueyoshi Turumi-ku Yokohama, Kanagawa

TEL

045-571-6140

Email

s-mori-ab@morinaga.co.jp


Public contact

Name of contact person

1st name Sadao
Middle name
Last name Mori

Organization

MORINAGA & CO., LTD.

Division name

R & D Center

Zip code

230-8504

Address

2-1-1 Shimosueyoshi Turumi-ku Yokohama, Kanagawa

TEL

045-571-6140

Homepage URL


Email

s-mori-ab@morinaga.co.jp


Sponsor or person

Institute

MORINAGA & CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

MORINAGA & CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

NPO MINS

Address

401 5-20-9 mita minato-ku Tokyo

Tel

03-6416-1868

Email

npo-mins@j-irb.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

松生クリニック(東京都)


Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 30 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

82

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2020 Year 11 Month 11 Day

Date of IRB

2020 Year 11 Month 12 Day

Anticipated trial start date

2020 Year 11 Month 25 Day

Last follow-up date

2021 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 05 Month 06 Day

Last modified on

2022 Year 02 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048570


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name